#aidsmap

Programs that seek to discourage the sharing of drug injection equipment can also lower the risk of hepatitis C by encouraging less frequent s...

Harm reduction programs for injection drug users that focus on risks might be more effective if they instead highlighted pleasure.

People with hepatitis B and cirrhosis should be prioritized for liver cancer screening, which is cost-effective among this population.

While people with HIV are typically tested for hepatitis C upon entering care, follow-up hep C screens are less common.

A comprehensive harm reduction program instituted by the Scottish government has sharply reduced hepatitis C rates among injection drug users.

As prescription drug abuse leads more Americans on a path to heroin, new cases of hepatitis C are rising among young people in non-urban areas...

An intervention for couples who use drugs lowers their risk of contracting hepatitis C virus as well as raises their rate of condom use.

AbbVie’s ’3D’ regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV

People coinfected with HIV and hepatitis C have a higher risk of osteoporosis and bone fracture than those who are infected with just HIV.

Curing hepatitis C reduces central fatigue, which is weakness originating in the central nervous system.

A fixed-dose combo pill of Sovaldi and ledipasvir is poised to boast a 100 percent success rate in curing hepatitis C among those coinfected w...

Low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C, but just two thirds...

The apparent fact that transmission pathways for hepatitis C and HIV frequently converge may help better tailor prevention efforts.

Men coinfected with HIV and hepatitis C are at reduced risk of developing decompensated liver disease after beginning HIV treatment.

Dried blood contaminated with Hepatitis C and left on inanimate surfaces can remain infectious in ordinary room temperatures for up to six wee...

A study has found that treating hepatitis B with Baraclude (entecavir) reduces the lifetime risk of developing liver cancer.